Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio

Aug 08 2016

• By Mandy Jackson

formula

Related Content

Helsinn’s Family-Business Approach Goes Global In Cancer Care

Mar 09 2015

MEI Pharma plummets on Phase II HDAC data

Mar 25 2015

Case Studies: How Three Public Companies Financed R&D In A Tough Market

Jul 26 2016

Related Companies

Helsinn Healthcare SA

Lite Strategy, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Spectrum Pharmaceuticals, Inc.

Novartis AG

Syndax Pharmaceuticals, Inc.

Additional Topics

Commercial Deals BioPharmaceutical Cancer

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.